- Home
- MGEE vs SRRK Comparison
MGEE vs SRRK Comparison
Compare MGEE & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGEE
- SRRK
- Stock Information
- Founded
- MGEE 1855
- SRRK 2012
- Country
- MGEE United States
- SRRK United States
- Employees
- MGEE N/A
- SRRK N/A
- Industry
- MGEE Electric Utilities: Central
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGEE Energy
- SRRK Health Care
- Exchange
- MGEE Nasdaq
- SRRK Nasdaq
- Market Cap
- MGEE 3.8B
- SRRK 3.1B
- IPO Year
- MGEE N/A
- SRRK 2018
- Fundamental
- Price
- MGEE $89.98
- SRRK $31.52
- Analyst Decision
- MGEE Sell
- SRRK Strong Buy
- Analyst Count
- MGEE 1
- SRRK 6
- Target Price
- MGEE $80.00
- SRRK $42.17
- AVG Volume (30 Days)
- MGEE 109.7K
- SRRK 1.4M
- Earning Date
- MGEE 05-07-2025
- SRRK 05-14-2025
- Dividend Yield
- MGEE 1.99%
- SRRK N/A
- EPS Growth
- MGEE 6.51
- SRRK N/A
- EPS
- MGEE 3.54
- SRRK N/A
- Revenue
- MGEE $687,578,000.00
- SRRK N/A
- Revenue This Year
- MGEE $9.95
- SRRK N/A
- Revenue Next Year
- MGEE $3.02
- SRRK $601.05
- P/E Ratio
- MGEE $26.05
- SRRK N/A
- Revenue Growth
- MGEE 6.11
- SRRK N/A
- 52 Week Low
- MGEE $72.27
- SRRK $6.76
- 52 Week High
- MGEE $109.22
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- MGEE 47.91
- SRRK 48.20
- Support Level
- MGEE $89.28
- SRRK $32.10
- Resistance Level
- MGEE $91.50
- SRRK $33.48
- Average True Range (ATR)
- MGEE 2.15
- SRRK 1.75
- MACD
- MGEE 0.12
- SRRK -0.01
- Stochastic Oscillator
- MGEE 62.34
- SRRK 38.04
About MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings. MGE's generation mix is 40% coal, 21% renewable energy, 17% natural gas, and third-party purchased power.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.